Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma
Protocol ID
ANBL1821
Disease (Sub Disease)
Solid tumours (Neuroblastoma)
Diagnosis Stage
Relapse/refractory
Location
NSW, QLD, VIC, WA, SA, NZ
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Links
External Registry ≫
Trial Status
Open
Sites
Perth Children's Hospital
Queensland Children's Hospital
The Children's Hospital at Westmead
Sydney Children's Hospital
Royal Children's Hospital
Christchurch Hospital
Starship Hospital
John Hunter Children's Hospital
Women's & Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year and older
International registry ID's
NCT03794349
Back to Registry
Study Title A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma
Protocol ID ANBL1821
Disease (Sub Disease) Solid tumours (Neuroblastoma)
Diagnosis Stage Relapse/refractory
Location NSW / QLD / VIC / WA / SA / NZ
Sponsor Children's Oncology Group
Collaborators National Cancer Institute (NCI)
Links https://clinicaltrials.gov/ct2/show/NCT03794349
Trial Status Open
Trial Open Date 28/05/2019
Sites Perth Children's Hospital / Queensland Children's Hospital / The Children's Hospital at Westmead/ Sydney Children's Hospital / Royal Children's Hospital / Christchurch Hospital / Starship Hospital / John Hunter Children's Hospital/ Women's & Children's Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility 1 Year and older
International registry ID's NCT03794349